InSilico Medicine bags award for Pharma.AI platform
It was recognised for creating a generative AI-driven platform for broad drug discovery.
Insilico Medicine has been developing AI platforms that utilise deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties.
As a clinical stage biotech company powered by generative AI, it connects biology, chemistry, and clinical trials analysis using next- generation AI systems.
It is committed to developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
Its most recently launched platform is the Pharma.AI, the only generative AI-powered drug discovery and development platform that provides end-to-end drug discovery and development services from discovery of novel target to generation of novel small molecule and prediction of clinical outcome.
Compared to companies that only use AI for optimisation, the Pharma.AI platform has fully generated the entire pipeline of 31 programs and 29 drug targets.
In addition, it can be integrated with external tools such as ChatGPT to take advantage of the latest technological breakthroughs and create customised solutions for different customer needs.
Pharma.AI receives data collected from the pipeline development progress and from the strategic drug discovery and development collaborations, creating a flywheel effect that feeds into the deep machine learning element of its platform. As a result, this enables it to drive the continuous improvement of its end-to-end capabilities.
This technology is augmented by a robust team of biologists, chemists and AI specialists guided by a management team and advisors with deep industry experience in drug development.
Leveraging the platform, after completing Phase 0 and Phase I human safety studies, Insilico’s AI-discovered and AI-generated drug INS018_055 has entered multi-regional Phase II clinical trials in the U.S and China.
For this platform, the company was given the AI – Pharmaceuticals award in the recently concluded Hong Kong Business Technology Excellence Awards. Now in its fourth-year run, the awards programme recognises outstanding companies that made exceptional contributions in pursuit of technological innovation.
In selecting the winners, it crowned the best first-rate firms with the most innovative and unique IT initiatives and solutions that helped push forward doing business in Hong Kong.
The judging panel took into consideration the three major achievements of the company from launching the Pharma.AI platform.
First is that its Core Product, ISM001-055, has entered multi-regional Phase II clinical trials in the U.S and China. The company said that this is being considered as the first drug discovered and designed with generative AI that has entered Phase II trials having first patients dosed.
The second achievement is that Insilico Medicine has nominated 9 preclinical candidates for 2022 alone and has advanced 4 of internal pipelines to the clinical stage with the support of its proprietary AI platform.
Third, and lastly, Insilico & solution demonstrates substantial business value. Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2b with $ 21.5m upfront for 6 targets drug discovery and development in Nov 2022. Moreover, Insilico also reached a collaboration with Exelixis, realising the first AI drug out-licensing in APAC in Sept 2023. Insilico will get $80m upfront payment, as well as milestone payments and royalty splits.
Taken together, these achievements were only made possible with the Pharma.AI being at the forefront in changing the pharmaceuticals industry.
The Hong Kong Business Technology Excellence Awards is presented by Hong Kong Business Magazine. To view the full list of winners, click here. If you want to join the 2024 awards programme and be acclaimed for your company's outstanding contributions in pursuit of technological innovation, please contact Julie Anne Nuñez at email@example.com.